Flex Pharma (NASDAQ: FLKS) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Flex Pharma to related companies based on the strength of its risk, profitability, analyst recommendations, earnings, valuation, institutional ownership and dividends.
Valuation and Earnings
This table compares Flex Pharma and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Flex Pharma||$1.01 million||-$39.49 million||-1.87|
|Flex Pharma Competitors||$284.28 million||$34.29 million||132.91|
Insider and Institutional Ownership
27.3% of Flex Pharma shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 45.4% of Flex Pharma shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Flex Pharma and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Flex Pharma Competitors||-5,349.08%||-434.35%||-39.98%|
Risk and Volatility
Flex Pharma has a beta of 3.54, indicating that its stock price is 254% more volatile than the S&P 500. Comparatively, Flex Pharma’s competitors have a beta of 5.64, indicating that their average stock price is 464% more volatile than the S&P 500.
This is a breakdown of current recommendations for Flex Pharma and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Flex Pharma Competitors||848||3199||11599||230||2.71|
Flex Pharma presently has a consensus price target of $11.00, suggesting a potential upside of 191.78%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.33%. Given Flex Pharma’s stronger consensus rating and higher probable upside, analysts plainly believe Flex Pharma is more favorable than its competitors.
Flex Pharma Company Profile
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.